# EDGAR Filing Document

**Accession Number:** 0001796129
**File Stem:** 0001193125-25-142729
**Filing Date:** 2025-6
**Character Count:** 8018
**Document Hash:** d5d0685182a26c6895daeceb7e09c6bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-142729.hdr.sgml**: 20250618

**ACCESSION NUMBER**: 0001193125-25-142729

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250618

**DATE AS OF CHANGE**: 20250618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vincerx Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001796129
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 833197402
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39244
- **FILM NUMBER:** 251057205

**BUSINESS ADDRESS:**
- **STREET 1:** 260 SHERIDAN AVENUE
- **STREET 2:** SUITE 400
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94306
- **BUSINESS PHONE:** 650-800-6676

**MAIL ADDRESS:**
- **STREET 1:** 260 SHERIDAN AVENUE
- **STREET 2:** SUITE 400
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94306

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vincera Pharma, Inc.
- **DATE OF NAME CHANGE:** 20201223

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LifeSci Acquisition Corp.
- **DATE OF NAME CHANGE:** 20191206

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**SCHEDULE 14A** 

**(RULE 14a-101)** 

**SCHEDULE 14AINFORMATION** 

**Proxy Statement Pursuant To Section 14(a) of the** 

**Securities Exchange Act of 1934** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under§ 240.14a-12

**VINCERX PHARMA, INC.** 

**(Name of Registrant as Specified In Its Charter)** 

**(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11

------

**[Press release issued June 18, 2025]** 

**Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene** 

**Meeting on July 16 , 2025 to Secure Votes Needed to Approve Dissolution Proposal** 

***Failure to approve Dissolution Proposal will reduce or eliminate***

***any potential distributions to stockholders***

**San Mateo, California, June 18, 2025** – Vincerx Pharma, Inc. today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at <u>www.virtualshareholdermeeting.com/VINC2025SM2</u>. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal.

**Vincerx is urging ALL stockholders to vote IMMEDIATELY <u>FOR</u> the Dissolution Proposal.** 

Vincerx's board of directors unanimously recommends that stockholders vote **<u>FOR</u>** the Dissolution Proposal and believes that approval of the Dissolution Proposal is extremely important to stockholders for a number of reasons, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Preserve Possibility of Distributions**. Vincerx is hopeful that cash will be available for distribution to
its stockholders. However, further delays in approving the Dissolution Proposal will result in continued public company and other operating costs and expenses - reducing or eliminating what funds could remain for distribution to stockholders.
Approving the Dissolution Proposal will allow Vincerx to move forward expeditiously and maximize the likelihood of a distribution to its stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Recognize Potential Tax Benefits**. U.S. stockholders who receive less than their tax basis in their shares
could be eligible to recognize a capital loss for U.S. federal income tax purposes. Timely approval of the Dissolution Proposal will facilitate this recognition.

"We believe it is extremely important that our stockholders vote **<u>FOR</u>** the Dissolution Proposal," said Dr. Raquel Izumi, Acting CEO. "We understand the disappointment that all of us who are stockholders and supported the company over the years feel, but approving the Dissolution Proposal at least gives stockholders the possibility of receiving some value for their shares. Delaying approval of the Dissolution Proposal will simply result in the company continuing to incur ongoing operating costs and expenses, which will only reduce or even eliminate the likelihood that there will be any amounts left for distribution to stockholders. We therefore urge all stockholders to vote **<u>FOR</u>** the Dissolution Proposal before the reconvened meeting on July 16, 2025."

<u>Every vote matters</u>. Stockholders must ACTIVELY VOTE for their vote to count. **Any delay in approving the Dissolution Proposal will result in increased expenditures and reduce the likelihood that amounts will be available for distribution to stockholders.**

------

**<u>Voting is quick and simple:</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** **BY PHONE: Please call Advantage Proxy, Vincerx's proxy solicitor, <u>toll-free</u> at <u>1-877-870-8565</u> between the hours of 9:00 a.m. and 9:00 p.m., Eastern Time, Monday through Friday. You can also contact Advantage Proxy if you have any questions about voting.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** **BY INTERNET: Vote by going to <u>www.proxyvote.com</u> and entering the control number on your proxy card or by following the instructions provided by your broker, bank, or other nominee.** 

**Your vote <u>FOR</u> the Dissolution Proposal is very important - please VOTE TODAY.** 

**Additional Information** 

Information regarding the Dissolution Proposal, including the board of director's reasons for recommending approval of the Dissolution Proposal, is set forth in the company's proxy statement and supplements thereto, which have been filed with the Securities and Exchange Commission ("SEC") and are available at the SEC's website at <u>www.sec.gov</u>.

**Forward-Looking Information** 

This press release contains forward-looking statements within the meaning of the federal securities laws including, but not limited to, statements about the reasons for approving, and the consequences of failing to approve, the Dissolution Proposal; the potential availability of amounts for distribution to stockholders; and the potential tax benefits to stockholders of approving the Dissolution Proposal. Forward-looking statements involve risks and uncertainties that may cause actual results or performance to differ materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks involved in dissolving, liquidating, and winding down Vincerx's business and affairs; the timing or amount of distributions, if any, to Vincerx's stockholders; stockholder approval of the Dissolution Proposal and the timeliness of such approval; the risk that Vincerx may need to seek protection of the bankruptcy court; and the other factors discussed in Vincerx's reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to Vincerx as of the date of this press release. Vincerx undertakes no duty or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Contact Information:** 

info@vincerx.com